Acute Myeloid Leukaemia Market Provides Industrial Survey and Key Opinion of Manufacturing Leaders; Analysis to 2020
Acute Myeloid Leukemia Market is a rare but serious disease, and the most common leukaemia suffered by adults. The first-line treatment in eligible patients is almost always intensive chemotherapy. Despite strong initial remission rates, relapse is common, and Acute Myeloid Leukemia Market has the lowest five-year survival rate of all leukaemia's, at 25%. However, a number of products are currently in late-stage development for the treatment of Acute Myeloid Leukemia Industry, both before and after the induction of remission and...
View full press release